Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LG Life Obtains Korea FDA Approval To Conduct Clinical Trials For Biosimilar Following Celltrion, Hanwha

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's LG Life Sciences became the third local pharma company to obtain Korea FDA approval to conduct clinical trials of its biosimilar, code-named LBEC0101, on the heels of clinical trial clearance for Celltrion and Hanwha Chemicals
Advertisement

Related Content

Samsung Bioepis Files Biosimilar Enbrel In South Korea
Korean Companies Step Up Development Of Enbrel Biosimilars As Amgen Ramps Up Its Pipeline
Korea Biosimilar Play LG Life Sciences Names New CEO Amid Unfriendly Business Conditions
Korea Biosimilar Play LG Life Sciences Names New CEO Amid Unfriendly Business Conditions
Korea's Celltrion Sells 10 Percent Of Its Shares To Singapore's Temasek To Fund Biosimilar Development
Korea's Celltrion Sells 10 Percent Of Its Shares To Singapore's Temasek To Fund Biosimilar Development
Korea's Samsung Electronics On Manhunt For Biosimilar Talent As Local Companies Keep Wary Eye On Competition
Korea's Celltrion Cuts Deal With Perrigo To Sell Its Biosimilars In Israel
Advertisement
UsernamePublicRestriction

Register

SC075340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel